Stem Cell Research & Therapy

Table 3 Summary of subgroup analysis of stem cells for the treatment of patients with CD

From: Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn’s disease

	Clinical response					Clinical remission					Fistula closure
Items	n	Heterogeneity		ES	95% CI	n	Heterogeneity		ES	95% CI	n	Heterogeneity		ES	95% CI
Items		I ²	P				I ²	P				I ²	P		95% CI
Overall	11	78.6%	<0.001	0.56	[0.33–0.76]	8	68.5%	0.002	0.46	[0.25–0.69]	12	59.9%	0.003	0.57	[0.44–0.69]
Source
HSC	0	-	-	-	-	4	75.9%	0.006	0.73	[0.36–0.93]	2	80.8%	0.022	0.29	[0.03–0.85]
BMSC	6	69.8%	0.005	0.59	[0.34–0.80]	4	60.1%	0.057	0.23	[0.07–0.54]	2	0.0%	0.740	0.60	[0.44–0.75]
ASC	5	84.6%	<0.001	0.51	[0.13–0.88]	0	-	-	-	-	9	65.3%	0.003	0.62	[0.42–0.79]
Source
Autologous	7	49.6%	0.064	0.31	[0.17–0.49]	5	76.4%	0.002	0.61	[0.25–0.88]	9	59.5%	0.011	0.62	[0.44–0.77]
Allogeneic	4	26.7%	0.251	0.86	[0.71–0.94]	3	56%	0.103	0.32	[0.11–0.62]	4	30.2%	0.231	0.47	[0.33–0.61]
Routine
Systemic	5	67.7%	0.001	0.66	[0.39–0.86]	8	68.5%	0.002	0.46	[0.25–0.69]	2	80.8%	0.023	0.29	[0.03–0.85]
Local	6	81.0%	<0.001	0.45	[0.16–0.79]	0	-	-	-	-	11	57.9%	0.002	0.60	[0.47–0.72]

Abbreviations: ASC adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, HSC hematopoietic stem cell

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com